New Additions to Drugs.com for 2018
We update the Drugs.com database on a regular cycle. The following new drug information has been added this year:
Jun 30, 2018 - Mektovi (binimetinib) is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Jun 30, 2018 - Braftovi (encorafenib) is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Jun 25, 2018 - Epidiolex (cannabidiol) is a cannabinoid product for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
Jun 6, 2018 - Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Jun 5, 2018 - Consensi (amlodipine and celecoxib) is a calcium channel blocker and nonsteroidal anti-inflammatory drug combination for the treatment of both hypertension and pain associated with osteoarthritis.
May 22, 2018 - Doptelet (avatrombopag) is a second generation orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical procedure.
May 21, 2018 - Aimovig (erenumab) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine.
May 17, 2018 - Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal.
Apr 18, 2018 - Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).
Mar 22, 2018 - Ilumya (tildrakizumab-asmn) is an anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.
Mar 14, 2018 - Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults.
Mar 12, 2018 - Cimduo (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleo(t)side reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Mar 12, 2018 - Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Mar 7, 2018 - Apadaz (acetaminophen and benzhydrocodone hydrochloride) is an immediate release combination of acetaminophen and benzhydrocodone, a prodrug of the opioid agonist hydrocodone, indicated for the short-term management of acute pain.
Feb 14, 2018 - Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC).
Feb 13, 2018 - Symdeko (ivacaftor/tezacaftor tablets and ivacaftor tablets) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combination for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with Symdeko.
Feb 7, 2018 - Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) is an integrase strand transfer inhibitor and emtricitabine/tenofovir alafenamide (Descovy) combination for the treatment of HIV-1 infection in adults.
Jan 25, 2018 - Segluromet (ertugliflozin and metformin hydrochloride) is a sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination used to improve glycemic control in adults with type 2 diabetes.
Jan 25, 2018 - Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.